C07K 14/70578
Ngf-receptor/tnf-receptor superfamily
Official title: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
C07K14/70578 (Ngf-receptor/tnf-receptor superfamily) appears on 1,552 US grants and 3,218 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,552
- Published applications
- 3,218
- Assignees
- 884
- Inventors
- 4,145
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 15 | 0 |
| 2000 | 14 | 0 |
| 2001 | 24 | 5 |
| 2002 | 23 | 79 |
| 2003 | 26 | 527 |
| 2004 | 17 | 71 |
| 2005 | 28 | 69 |
| 2006 | 39 | 53 |
| 2007 | 87 | 33 |
| 2008 | 82 | 28 |
| 2009 | 36 | 32 |
| 2010 | 35 | 41 |
| 2011 | 21 | 29 |
| 2012 | 22 | 30 |
| 2013 | 19 | 44 |
| 2014 | 30 | 54 |
| 2015 | 25 | 53 |
| 2016 | 39 | 77 |
| 2017 | 36 | 94 |
| 2018 | 38 | 128 |
| 2019 | 64 | 156 |
| 2020 | 99 | 199 |
| 2021 | 118 | 315 |
| 2022 | 118 | 265 |
| 2023 | 92 | 232 |
| 2024 | 143 | 250 |
| 2025 | 147 | 207 |
| 2026 | 100 | 147 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy8 Oct 2026US 2026/0308519 A1The Trustees of the University of Pennsylvania
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Chimeric antigen receptor targeting bcma and use thereof1 Oct 2026US 2026/0295044 A1Shenzhen Cell Valley Biomedical Co., Ltd.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Binary encoded sequence tags224US 6,773,886 B2Agilix Corporation · 2004
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014